Last year featured slower merger and acquisition (M&A) activity than 2023 and a moderate uptick in alliances. Here, we highlight the trends and key deals. The transactions analysed include those in the biopharma industry, as well as consumer and over-the-counter companies, drug delivery technologies, contract research and clinical trial services, but exclude devices, diagnostics, research tools, animal health and insurance.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The authors declare no competing interests.
